Intracranial aneurysms are common, and the risk of rupture is influenced by size, location, morphology, and factors such as ...

A total of 14 million Medicare beneficiaries receive the Low-Income Subsidy (LIS), which reduces cost sharing in Medicare Part D. Losing the LIS may impede medication access and affect mortality.

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of these symptoms) for more than 6 weeks. Remibrutinib, an oral, highly ...

Chemoimmunotherapy was the standard treatment for chronic lymphocytic leukemia (CLL), although it has now been largely replaced by targeted therapies. 1-3 Available targeted therapies include ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when ...

There is growing concern about the well-being of physicians and the consequences of poor well-being for physicians themselves, their patients, and the broader health care system. Diminished well ...

Hairy-cell leukemia (HCL) is a rare, indolent neoplasm of mature B cells with hairlike surface projections that circulate in the blood and preferentially infiltrate the bone marrow and spleen.

EBV is one of the most successful viruses, infecting over 90 percent of humans and persisting for the lifetime of the person. EBV is closely related to viruses present in Old World nonhuman ...

In this review, we first provide a brief overview of frailty, including biologic mechanisms, measurement, and clinical management. This overview is followed by a discussion of approaches to ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when ...

Care of patients with systemic immunoglobulin light chain (AL) amyloidosis has undergone transformative changes, leading to marked, steady progress in outcomes for patients over the past four decades.

Dupilumab is a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by type 2 inflammation, including ...